Development and validation of a pen side test for Rift Valley fever

Cêtre-Sossah, Catherine; Pédarrieu, Aurélie; Juremalm, Mikael; Vuren, Petrus Jansen van; Brun, Alejandro; Mamy, Ahmed B. Ould El; Héraud, Jean Michel; Filippone, Claudia; Ravalohery, Jean-Pierre; Chaabihi, Hassan; Albina, Emmanuel; Dommergues, Laure; Pawęska, Janusz T.; Cardinale, Éric

doi:10.1371/journal.pntd.0007700

Cited by 18 publications

(15 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A pen-side test or lateral flow immunochromatographic strip test for detection of the nucleoprotein of RVFV was developed. This type of assay helps to better manage the early diagnosis and control of RVF in the case of ongoing outbreaks (13).…”

Section: Diagnosismentioning

confidence: 99%

Rift Valley fever – a growing threat to humans and animals

Kwasnik

Rozek

Rola

2021

Journal of Veterinary Research

View full text Add to dashboard Cite

Rift Valley fever (RVF) is a zoonotic, vector-borne infectious disease of ruminants and camels transmitted mainly by the Aedes and Culex mosquito species. Contact with the blood or organs of infected animals may infect humans. Its etiological factor is the Rift Valley fever virus (RVFV) of the Phlebovirus genus and Bunyaviridae family. Sheep and goats are most susceptible to infection and newborns and young individuals endure the most severe disease course. High abortion rates and infant mortality are typical for RVF; its clinical signs are high fever, lymphadenitis, nasal and ocular secretions and vomiting. Conventional diagnosis is done by the detection of specific IgM or IgG antibodies and RVFV nucleic acids and by virus isolation. Inactivated and live-attenuated vaccines obtained from virulent RVFV isolates are available for livestock. RVF is endemic in sub-Saharan Africa and the Arabian Peninsula, but in the last two decades, it was also reported in other African regions. Seropositive animals were detected in Turkey, Tunisia and Libya. The wide distribution of competent vectors in non-endemic areas coupled with global climate change threaten to spread RVF transboundarily. The EFSA considers the movement of infected animals and vectors to be other plausible pathways of RVF introduction into Europe. A very low risk both of introduction of the virus through an infected animal or vector and of establishment of the virus, and a moderate risk of its transmission through these means was estimated for Poland. The risk of these specific modes of disease introduction into Europe is rated as very low, but surveillance and response capabilities and cooperation with the proximal endemic regions are recommended.

show abstract

Section: Diagnosismentioning

confidence: 99%

Rift Valley fever – a growing threat to humans and animals

Kwasnik

Rozek

Rola

2021

Journal of Veterinary Research

View full text Add to dashboard Cite

show abstract

“…Only one device for the rapid detection of RVFV has been reported. 75 The first-line lateral flow immunochromatographic strip test was developed to detect nucleoprotein (N) of the RVFV, cf. Fig.…”

Section: Rapid Test For the Detection Of Rvfvmentioning

confidence: 99%

Commercially available rapid diagnostic tests for the detection of high priority pathogens: status and challenges

Castillo-León

Trebbien

Castillo

et al. 2021

Analyst

View full text Add to dashboard Cite

show abstract

“…A report of a pen side veterinary test for diagnosis of RVF using chromatographic strips has also been published. 42 This method uses gold-labelled monoclonal antibodies against RVFV N protein and has a detection limit of 10 3 –10 5 pfu depending on the strain. This rapid test lacks quantitative results but could be used for first-line testing of livestock to detect early stages of suspected disease transmission, and serve as an early warning of potential subsequent human outbreaks.…”

Section: Diagnostics For Rvfv Detectionmentioning

confidence: 99%

Rift valley fever: diagnostic challenges and investment needs for vaccine development

Petrova

Kristiansen

Norheim³

et al. 2020

BMJ Glob Health

View full text Add to dashboard Cite

Rift valley fever virus (RVFV) is a causative agent of a viral zoonosis that constitutes a major clinical burden in wild and domestic ruminants. The virus causes major outbreaks in livestock (sheep, goats, cattle and camels) and can be transmitted to humans by contaminated animal products or via arthropod vectors. Human-to-human transmission has not been reported to date, but spill-over events from animals have led to outbreaks in humans in Africa and the Arabian Peninsula. Currently, there is no licensed human vaccine against RVFV and the virus is listed as a priority pathogen by the World Health Organisation (WHO) due to the high epidemic potential and the lack of effective countermeasures. Multiple large RVFV outbreaks have been reported since the virus was discovered. During the last two decades, over 4000 cases and ~1000 deaths have been reported. The lack of systematic surveillance to estimate the true burden and incidence of human RVF disease is a challenge for planning future vaccine efficacy evaluation. This creates a need for robust diagnostic methodologies that can be deployed in remote regions to aid case confirmation, assessment of seroprevalence as well as pathogen surveillance required for the different stages of vaccine evaluation. Here, we perform comprehensive landscaping of the available diagnostic solutions for detection of RVFV in humans. Based on the identified gaps in the currently available in-house and commercially available methods, we highlight the specific investment needs for diagnostics that are critical for accelerating the development of effective vaccines against RVFV.

show abstract

Development and validation of a pen side test for Rift Valley fever

Cited by 18 publications

References 40 publications

Rift Valley fever – a growing threat to humans and animals

Rift Valley fever – a growing threat to humans and animals

Commercially available rapid diagnostic tests for the detection of high priority pathogens: status and challenges

Rift valley fever: diagnostic challenges and investment needs for vaccine development

Contact Info

Product

Resources

About